Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates
- PMID: 22493797
- PMCID: PMC4605348
- DOI: 10.1002/mabi.201100340
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates
Abstract
Biodistribution, pharmacokinetics, and efficacy of prostate-cancer-targeted HPMA copolymer/DTX conjugates are evaluated in nude mice bearing prostate cancer C4-2 xenografts. PSMA-specific monoclonal antibodies 3F/11 are used as the targeting moiety. Control conjugates tumor accumulation to total background organs (heart, lung, kidney, liver, spleen and blood) accumulation increase substantially with time for the targeted conjugate, and the ratio at 48 h is 7-fold higher than that at 6 h. Preliminary evaluation of the efficacy of the conjugates in vivo show tumor growth inhibition for all HPMA copolymer/DTX conjugates.
Figures
Similar articles
-
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.J Drug Target. 2013 Dec;21(10):968-80. doi: 10.3109/1061186X.2013.833207. J Drug Target. 2013. PMID: 24160903 Free PMC article.
-
Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.Mol Pharm. 2011 Aug 1;8(4):1090-9. doi: 10.1021/mp100402n. Epub 2011 Jun 1. Mol Pharm. 2011. PMID: 21599008 Free PMC article.
-
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.Clin Cancer Res. 2006 Apr 15;12(8):2591-6. doi: 10.1158/1078-0432.CCR-05-2107. Clin Cancer Res. 2006. PMID: 16638870
-
HPMA copolymer-cyclic RGD conjugates for tumor targeting.Adv Drug Deliv Rev. 2010 Feb 17;62(2):167-83. doi: 10.1016/j.addr.2009.11.027. Epub 2009 Dec 4. Adv Drug Deliv Rev. 2010. PMID: 19951733 Review.
-
Molecular imaging of HPMA copolymers: visualizing drug delivery in cell, mouse and man.Adv Drug Deliv Rev. 2010 Feb 17;62(2):246-57. doi: 10.1016/j.addr.2009.12.007. Epub 2010 Jan 7. Adv Drug Deliv Rev. 2010. PMID: 20060431 Review.
Cited by
-
A Nanostrategy for Efficient Imaging-Guided Antitumor Therapy through a Stimuli-Responsive Branched Polymeric Prodrug.Adv Sci (Weinh). 2020 Jan 31;7(6):1903243. doi: 10.1002/advs.201903243. eCollection 2020 Mar. Adv Sci (Weinh). 2020. PMID: 32195104 Free PMC article.
-
HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.J Control Release. 2013 Dec 28;172(3):946-53. doi: 10.1016/j.jconrel.2013.09.005. Epub 2013 Sep 14. J Control Release. 2013. PMID: 24041709 Free PMC article.
-
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.J Drug Target. 2013 Dec;21(10):968-80. doi: 10.3109/1061186X.2013.833207. J Drug Target. 2013. PMID: 24160903 Free PMC article.
References
-
- Kopeček J. Polim Med. 1977;7:191. - PubMed
-
- Lammers T. Adv Drug Delivery Rev. 2010;62:203. - PubMed
-
- Duncan R, Vicent MJ. Adv Drug Delivery Rev. 2010;62:272. - PubMed
-
- Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. J Clin Oncol. 2002;20:1668. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous